<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pegaptanib (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pegaptanib (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pegaptanib (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11243" href="/d/html/11243.html" rel="external">see "Pegaptanib (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F206719"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Macugen [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F206733"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ophthalmic Agent;</li>
<li>
                        Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F206720"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">
<b>Note:</b> Macugen has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="26d2a366-da86-493f-8c04-7a7133fc68c7">Macular degeneration</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Macular degeneration (</b>
<b>neovascular age-related<b>):</b></b> Intravitreous injection: 0.3 mg into affected eye once every 6 weeks.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990146"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987475"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F3062246"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F206697"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, decreased visual acuity, eye discharge, eye discomfort, eye irritation, eye pain, increased intraocular pressure, punctate keratitis, visual disturbance, vitreous opacity</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cerebrovascular accident (1% to 5%), chest pain (1% to 5%), occlusive arterial disease (carotid artery: 1% to 5%), transient ischemic attacks (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (6% to 10%), headache (6% to 10%), vertigo (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (6% to 10%), nausea (6% to 10%), dyspepsia (1% to 5%), vomiting (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (6% to 10%), urinary retention (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise (1% to 5%), periorbital hematoma (1% to 5%), vitreous hemorrhage (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local inflammation (eye: 1% to 5%), local irritation (eyelid: 1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis (1% to 5%), bone spur (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (6% to 10%), conjunctivitis (6% to 10%), photopsia (6% to 10%), vitreous disorder (6% to 10%; includes inflammation), allergic conjunctivitis (1% to 5%), conjunctival edema (1% to 5%), corneal abrasion (1% to 5%), corneal deposits (1% to 5%), epithelial keratopathy (1% to 5%), endophthalmitis (1% to 5%), meibomianitis (1% to 5%), mydriasis (1% to 5%), retinal edema (1% to 5%), swelling of eye (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (6% to 10%), pleural effusion (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Accidental injury, anaphylactoid reaction, anaphylaxis, angioedema, arthropathy, blindness, choroidal detachment, colonic polyps, decreased white blood cell count, dysphagia, feeling abnormal, foreign body sensation of eye, giant-cell arteritis, hematochezia, hemoptysis, hemorrhage, iatrogenic traumatic cataracts, immune thrombocytopenia, increased heart rate, inflammation, intracranial hemorrhage, iridocyclitis, iritis, loss of consciousness, mass (pulmonary), musculoskeletal chest pain, myalgia, neuritis, non-small-cell lung carcinoma (adenocarcinoma), obstructive pulmonary disease, ocular hyperemia, pain, pain at injection site, prolonged partial thromboplastin time, pulmonary disease, pulmonary hemorrhage, retinal detachment, retinal hole without detachment, sclera disease, skin rash, sprue-like symptoms, subretinal neovascularization, syncope, tremor, urticaria, uveitis (intermediate)</p></div>
<div class="block coi drugH1Div" id="F206710"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to pegaptanib or any component of the formulation; ocular or periocular infections</p></div>
<div class="block war drugH1Div" id="F206695"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Endophthalmitis/retinal detachment: Intravitreous injections are associated with endophthalmitis. Proper aseptic injection techniques should be used and patients should be instructed to report any signs of infection (eg, eye pain or redness, photophobia, blurred vision) immediately. Retinal detachment and iatrogenic traumatic cataract have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Rare hypersensitivity reactions (including anaphylaxis/anaphylactoid reactions and angioedema) have been associated with use, occurring within several hours of use; monitor closely. Equipment and appropriate personnel should be available for monitoring and treatment of anaphylaxis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure: Intraocular pressure may increase within 30 minutes following intravitreal injection. Monitor intraocular pressure and optic nerve perfusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolic events: Thromboembolic events (eg, nonfatal stroke/MI, vascular death) have been reported following intravitreal administration of other VEGF inhibitors.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Concurrent administration in both eyes: Safety and efficacy for administration into both eyes concurrently have not been studied.</p></div>
<div class="block prod-avail drugH1Div" id="F56319363"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Macugen has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F206704"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intraocular [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Macugen: 0.3 mg (0.09 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F206693"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323629"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Macugen Intraocular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.3 mg (per 0.09 mL): $889.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F206707"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For ophthalmic intravitreal injection only. Attach a 30 gauge  <sup>1</sup>/<sub>2</sub> inch needle to the medication syringe. Slowly depress plunger to expel excess air and medication (refer to product labeling for detailed instructions). Injection should be performed under aseptic conditions. Adequate anesthesia and a topical broad spectrum antibiotic should be administered prior to the procedure.</p></div>
<div class="block use drugH1Div" id="F206706"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Macular degeneration (neovascular age-related):</b> Treatment of neovascular (wet) age-related macular degeneration (AMD)</p></div>
<div class="block mst drugH1Div" id="F14188872"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Pegaptanib may be confused with PAZOPanib, pegcetacoplan, peginesatide, pegaspargase, pegfilgrastim, peginterferon, pegvisomant, PONATinib</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299828"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Inhibits</b> CYP2J2 (weak)</p></div>
<div class="block dri drugH1Div" id="F6222174"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Pegloticase: May diminish the therapeutic effect of PEGylated Drug Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvaliase: PEGylated Drug Products may enhance the adverse/toxic effect of Pegvaliase. Specifically, the risk of anaphylaxis or hypersensitivity reactions may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53638444"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in females of reproductive potential. Based on information from other VEGF inhibitors, women of reproductive potential should use effective contraception prior to initial dose, during treatment, and for at least 3 months after the last intravitreal injection (Peracha 2016).</p></div>
<div class="block pri drugH1Div" id="F206712"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pegaptanib is a vascular endothelial growth factor (VEGF) inhibitor; VEGF is required to achieve and maintain normal pregnancies. Reports of intravitreal VEGF inhibitor use in pregnancy are limited and information specific to use of pegaptanib has not been located (Peracha 2016). Based on studies in nonpregnant adults, VEGF inhibitors can alter systemic concentrations of VEGF and placental growth factor following intravitreal administration (Peracha 2016; Zehtner 2015). Until additional information is available, intravitreal use during the first trimester should be avoided and use later in pregnancy should be based on patient specific risks versus benefits (Peracha 2016; Polizzi 2015).</p></div>
<div class="block brc drugH1Div" id="F20617527"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if pegaptanib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer recommends that caution be exercised when administering pegaptanib to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F206702"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Optic nerve head perfusion (immediately after injection), intraocular pressure (within 30 minutes and during the week after injection); signs of infection/inflammation (for first week following injection) or hypersensitivity; retinal perfusion, endophthalmitis, visual acuity</p></div>
<div class="block pha drugH1Div" id="F206694"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pegaptanib is an apatamer, an oligonucleotide covalently bound to polyethylene glycol, which can adopt a three-dimensional shape and bind to vascular endothelial growth factor (VEGF). Pegaptanib binds to extracellular VEGF, selectively inhibiting VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.</p></div>
<div class="block phk drugH1Div" id="F206709"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Slow systemic absorption following intravitreous injection</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized by endo- and exonucleases</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Plasma: 10 ± 4 days</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4301439"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Macugen | Pegaptanib</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Macugen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Ophthalmology Retina/Vitreous Panel Preferred Practice Pattern® Guidelines, "Age-Related Macular Degeneration," San Francisco, CA: American Academy of Ophthalmology; 2011 Available at http://www.aao.org. Accessed May 24, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15625332">
<a name="15625332"></a>Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for Neovascular Age-Related Macular Degeneration. <i>N Engl J Med.</i> 2004;351(27):2805-2816.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegaptanib-united-states-not-available-drug-information/abstract-text/15625332/pubmed" id="15625332" target="_blank">15625332</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Macugen (pegaptanib) [prescribing information]. Bridgewater, NJ: Bausch &amp; Lomb. July 2016.</div>
</li>
<li>
<div class="reference">
                  Peracha ZH, Rosenfeld PJ. Anti-vascular endothelial growth factor therapy in pregnancy: what we know, what we don't know, and what we don't know we don't know. <i>Retina</i>. 2016;36(8):1413-1417.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26302032">
<a name="26302032"></a>Polizzi S, Mahajan VB. Intravitreal anti-VEGF injections in pregnancy: case series and review of literature. <i>J Ocul Pharmacol Ther</i>. 2015;31(10):605-610.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegaptanib-united-states-not-available-drug-information/abstract-text/26302032/pubmed" id="26302032" target="_blank">26302032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26024110">
<a name="26024110"></a>Zehetner C, Bechrakis NE, Stattin M, et al. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy. <i>Invest Ophthalmol Vis Sci</i>. 2015;56(5):3279-3286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pegaptanib-united-states-not-available-drug-information/abstract-text/26024110/pubmed" id="26024110" target="_blank">26024110</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10182 Version 126.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
